Evan S Dellon
University of North Carolina, Chapel Hill · UNC Chapel Hill
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
9
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
NIH RePORTER
Trial papers
68
PubMed author-name match
Trials
Studies that name Evan S Dellon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07588568 · A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisUniversity of North Carolina, Chapel Hill · recruiting · EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE) · principal investigator
- Ph4NCT06352073 · Dupilumab for Eosinophilic Esophagitis With Severe StricturesUniversity of North Carolina, Chapel Hill · active not recruiting · Eosinophilic Esophagitis, EoE · principal investigator
- N/ANCT05543512 · The Immune Directed Individualized Elimination Therapy (iDIET) StudyUniversity of North Carolina, Chapel Hill · completed · Eosinophilic Esophagitis, EoE · principal investigator
- Ph2NCT03656380 · Mepo for Eosinophilic Esophagitis (EoE) StudyUniversity of North Carolina, Chapel Hill · completed · EoE, Eosinophilic Esophagitis · principal investigator
- N/ANCT02722148 · Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)University of North Carolina, Chapel Hill · completed · Eosinophilic Esophagitis · principal investigator
- Ph4NCT02019758 · Budesonide Versus Fluticasone for Treatment of Eosinophilic EsophagitisUniversity of North Carolina, Chapel Hill · completed · Eosinophilic Esophagitis · principal investigator
- N/ANCT01988285 · Risk Factors and Biomarkers for Diagnosis and Treatment of EoEUniversity of North Carolina, Chapel Hill · completed · Eosinophilic Esophagitis · principal investigator
- N/ANCT00961233 · Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)University of North Carolina, Chapel Hill · completed · Eosinophilic Esophagitis · principal investigator
- N/ANCT00685386 · A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP)University of North Carolina, Chapel Hill · completed · Cholestasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Trial of Upadacitinib for Non-responsive Eosinophilic esophagitis (ATUNE)R01DK146043 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2026 · $781,365 awarded in 2026Grant number is on one of their registry trials
- Clinical Research CoreP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2020 to 2026 · $164,186 awarded in 2026Same name and institution; not confirmed by an ID
- Porcine Related apprOach to Multidisciplinary cOllaborative Translational ModEl Research (PROMOTER)RC2TR005123 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2025 to 2026 · $770,559 awarded in 2026Same name and institution; not confirmed by an ID
- Short Term Research TrainingT35DK007386 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2023 to 2026 · $174,233 awarded in 2026Same name and institution; not confirmed by an ID
- Epidemiologic identification and mechanistic investigation of early life environmental risk factors for eosinophilic esophagitisR01ES031940 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2021 to 2025 · $625,444 awarded in 2025Same name and institution; not confirmed by an ID
- An allergen-specific immune signature-directed diet vs sham diet for treatment of eosinophilic esophagitis: A pilot-feasibility studyR01DK132001 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2022 to 2024 · $302,088 awarded in 2024Grant number is on one of their registry trials
- Molecular and epigenetic predictors and mechanisms of treatment response to topical steroids in eosinophilic esophagitisR21DK122297 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2020 to 2021 · $116,505 awarded in 2021Same name and institution; not confirmed by an ID
- Budesonide versus fluticasone for treatment of eosinophilic esophagitisR01DK101856 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2014 to 2018 · $330,600 awarded in 2018Grant number is on one of their registry trials
- Risk Factors and Biomarkers for Diagnosis & Treatment of Eosinophilic EsophagitisK23DK090073 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2011 to 2013 · $180,411 awarded in 2013Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:39 UTC. The ranking covers the 200 most relevant of 68 PubMed records, and a shared surname and initials can bring in a namesake. All 68 on PubMed
- Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.N Engl J Med · 2022415 citationsRCR 38.4
- Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.Gastroenterology · 2020373 citationsRCR 22.1
- 274 citationsRCR 12.0
- Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis.Gastroenterology · 2012267 citationsRCR 9.9
- Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.N Engl J Med · 2020235 citationsRCR 12.1
- RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.Gastroenterology · 2019224 citationsRCR 10.6
- Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis.J Allergy Clin Immunol · 2014223 citationsRCR 7.6
- Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.Gastroenterology · 2017201 citationsRCR 9.2
- Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.Gastroenterology · 2019159 citationsRCR 9.3
- Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.Clin Gastroenterol Hepatol · 2022132 citationsRCR 13.7